Valvular heart disease and calcification in CKD: more common than appreciated

Author:

Ureña-Torres Pablo12,D’Marco Luis34,Raggi Paolo5,García–Moll Xavier3,Brandenburg Vincent6,Mazzaferro Sandro7,Lieber Ari8,Guirado Lluis3,Bover Jordi3

Affiliation:

1. Department of Dialysis, AURA Nord Saint Ouen, Saint Ouen, France

2. Department of Renal Physiology, Necker Hospital, University of Paris Descartes, Paris, France

3. Fundació Puigvert, Department of Nephrology and Cardiology, IIB Sant Pau, RedinRen, Barcelona, Catalonia, Spain

4. Consorci Sanitari del Garraf, Department of Nephrology, Barcelona, Catalonia, Spain

5. Department of Medicine-Cardiology, University of Alberta, Edmonton, AB, Canada

6. Department of Cardiology and Intensive Care Medicine, RWTH University Hospital Aachen, Aachen, Germany

7. Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy

8. Department of Cardiology, Ramsay-Générale de Santé, Clinique du Landy, Saint Ouen, France

Abstract

Abstract Ischaemic heart disease, sudden cardiac death and arrhythmias, heart failure, stroke and peripheral arterial disease make up >50% of the causes of death in advanced chronic kidney disease (CKD). Calcification of the vascular tree and heart valves is partially related to these complications and has received growing attention in the literature. However, the main focus of research has been on the pathophysiology and consequences of vascular calcification, with less attention being paid to valvular calcification (VC) and its impact on the survival of CKD patients. Although VC has long been seen as an age-related degenerative disorder with minimal functional impact, several studies proved that it carries an increased risk of death and clinical consequences different from those of vascular calcification. In dialysis patients, the annual incidence of aortic valve calcification is nearly 3.3% and the reported prevalence of aortic and mitral VC varies between 25% and 59%. Moreover, calcification of both valves occurs 10–20 years earlier in CKD patients compared with the general population. Therefore, the purpose of this review is to summarize the current knowledge on the pathophysiology and relevance of VC in CKD patients, and to highlight specific clinical consequences and potential therapeutic implications.

Funder

Abbvie

Amgen

Astellas

Medici

Sanofi

Vifor-Pharma Fresenius MEdical Care and Hémotech

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3